Aarey Drugs & Pharmaceuticals Ltd

AGM Details & Resolutions

• AGM held on 30 September 2026, 03:00 PM to 03:20 PM, via OAVM.
• Resolution I: Adopt Audited Financial Statements for FY2025-26 with Directors' and Auditors' Reports.
• Resolution II: Re-appointment of Mrs. Bina Ghatalia, retiring by rotation.
• Resolution III: Approval of Related Party Transactions.
• Voting results to be submitted to stock exchanges within 2 working days.
• Scrutinizer for e-voting: Virendra G. Bhatt, Practising Company Secretary.

Capital action

• Allotted 11,50,000 equity shares on warrant conversion at Rs 47.85 per warrant
• Rs 55,027,500 received on conversion
• Post-conversion issued capital: 31,874,303 shares (₹318,743,030)
• 23,70,000 warrants converted on 06-08-2026
• 11,50,000 warrants converted on 30-09-2026
• 18-month conversion tenure from allotment date 23-05-2025

Shareholding disclosures

• Annexure I lists allottees and post-conversion holdings as of 30-09-2026
• Annexure A contains SEBI ICDR disclosures and investor details

Regulatory/compliance disclosures

• Regulatory disclosures under Regulation 30 and Schedule III of Listing Regulations included
• Annexure-A and Annexure-I contain conversion and allotment details

Worth Investment & Trading Co Limited trading window closed for Insiders, Designated Persons and their immediate relatives from Oct 01, 2026 till the completion of 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.

Aarey Drugs and Pharmaceuticals Limited trading window closes from October 1, 2026 until 48 hours after the unaudited financial results for the quarter and half year ended September 30, 2026.

AGM notice and Annual Report access

• 36th AGM scheduled for 30 September 2026 at 3:00 PM IST via VC/OAVM.
• Annual Report for FY 2025-26 available on the company's website.
• Weblink and exact path to Annual Report provided for registered and non-registered users.
• Letters issued to non-registered email holders with the annual report access link.
• Email-registration cut-off date: 04 September 2026.
• Investor queries to: investorgrievance@aareydrugs.com; Tel: 02239829999.
• Encourages Green Initiative and email updation to receive important communications.

Financials

• Revenue from operations: 47,226.90 lakhs in 2025-26; 47,394.33 lakhs in 2024-25.
• Profit after tax: 396.76 lakhs in 2025-26; 402.39 lakhs in 2024-25.
• EPS (basic/diluted): Rs 1.39 for 2025-26; Rs 1.41 for 2024-25.
• Dividend: no dividend recommended for 2025-26.
• Paid-up capital: Rs 28.45 crore; 28,454,303 shares.
• Promoter group holding: 37.71% as of 31 March 2026.

Capital structure & liquidity

• Short-term borrowings: Rs 4,898.76 lakh; long-term borrowings: Rs 97.40 lakh.
• Cash and cash equivalents: Rs 139.86 lakh.
• Credit rating: ACUITE BBB/Stable.
• Convertible warrants: 50 lakh warrants issued May 2025; 25% upfront.
• Subsidiaries: None.

Operations & strategy

• Product lines include Metformin HCL, Mefenamic Acid, Doxophylline; intermediates listed in MD&A.
• Intermediates include Mono Methyl Urea, Dimethyl Urea, Ortho Nitro Anisole.
• Capacity expansion planned across all products; backward/forward integration targeted (DMA-HCL, Ortho chloro benzoic acid, Theophylline).

Governance & compliance

• Regulatory: RPT policy disclosed on website; caps for related party transactions.
• Board: six members; two Executive Directors; three Independent Directors; one Woman Director.
• Loans to directors flagged as non-compliant with Section 185; details disclosed in notes.
• AGM: 36th meeting scheduled for 30 Sept 2026; VC/OAVM; remote e-voting.
• Secretarial audit flagged multiple non-compliances, including MGT-14 filings and related party disclosures.

Audit, risk & legal

• Emphasis of Matter: CWIP assets not yet used; depreciation to commence when usable.
• Debtors/creditors balances require confirmations; some balances not verified.
• Tax litigations pending; potential cash outflows uncertain.
• Auditors: Motilal & Associates LLP re-appointed for five-year term to 2030.

CSR & sustainability

• CSR obligation for 2025-26: Rs 11.64 lakh; actual spend: Nil.
• Unspent CSR: Rs 11.64 lakh to be transferred; prior year unspent Rs 14.25 lakh.
• CSR policy and projects disclosed on company website.

Promoters & shareholding

• Promoter group holding: 37.71% as of 31 March 2026.
• Promoters include Bina Ghatalia, Mihir Ghatalia, Nimit Ghatalia; detailed shareholding disclosed in the annual return.

Book closure for AGM

• Book closure for the 36th AGM; 24 Sep 2026 to 30 Sep 2026 (inclusive).